Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (27) 27
male (24) 24
psychiatry (23) 23
female (22) 22
adult (21) 21
index medicus (20) 20
middle aged (20) 20
pharmacology & pharmacy (18) 18
double-blind method (17) 17
cross-over studies (16) 16
abuse potential (11) 11
young adult (11) 11
adolescent (10) 10
dose-response relationship, drug (9) 9
pharmacokinetics (9) 9
analysis (8) 8
clinical neurology (7) 7
clinical trials (7) 7
dopamine (7) 7
drug abuse (7) 7
liability (6) 6
abuse liability (5) 5
alprazolam (5) 5
analgesics, opioid - administration & dosage (5) 5
analgesics, opioid - adverse effects (5) 5
dextromethorphan (5) 5
double-blind (5) 5
drug interactions (5) 5
liability assessment (5) 5
oxycodone (5) 5
pharmacotherapy (5) 5
research (5) 5
addiction (4) 4
c-oxidation (4) 4
cannabidiol (4) 4
central nervous system (4) 4
cigarette-smoking (4) 4
clinical (4) 4
dosage and administration (4) 4
hypnotics and sedatives - administration & dosage (4) 4
nicotine - metabolism (4) 4
opioid (4) 4
opioids (4) 4
pharmacology/toxicology (4) 4
quinidine (4) 4
safety (4) 4
smoking (4) 4
substance abuse (4) 4
substance-related disorders (4) 4
administration, intranasal (3) 3
administration, oral (3) 3
alprazolam - administration & dosage (3) 3
alprazolam - adverse effects (3) 3
alprazolam - pharmacology (3) 3
analgesics, opioid - pharmacokinetics (3) 3
animals (3) 3
aryl hydrocarbon hydroxylases - genetics (3) 3
behavioral sciences (3) 3
cannabinoid (3) 3
central nervous system depressants - pharmacology (3) 3
central nervous system stimulants - administration & dosage (3) 3
central nervous system stimulants - pharmacokinetics (3) 3
cocaine (3) 3
cytochrome p-450 cyp2a6 (3) 3
delayed-action preparations - administration & dosage (3) 3
delta-9-tetrahydrocannabinol (3) 3
drug liking (3) 3
drug users - psychology (3) 3
drug-related side effects and adverse reactions (3) 3
epilepsy (3) 3
ethanol (3) 3
extended release (3) 3
human liver-microsomes (3) 3
hypnotics and sedatives - adverse effects (3) 3
hypnotics and sedatives - pharmacology (3) 3
medicine & public health (3) 3
methylphenidate - pharmacokinetics (3) 3
mixed function oxygenases - genetics (3) 3
opioid-related disorders - prevention & control (3) 3
oral delta-tetrahydrocannabinol (3) 3
oxycodone - administration & dosage (3) 3
oxycodone - adverse effects (3) 3
partial-onset seizures (3) 3
pharmacology (3) 3
risk factors (3) 3
street drugs - adverse effects (3) 3
subjective (3) 3
tetrahydrocannabinol (3) 3
abuse (2) 2
abuse-deterrent formulations (2) 2
abuse-deterrent formulations - adverse effects (2) 2
acetamides - administration & dosage (2) 2
adults (2) 2
alcohol dependence (2) 2
amphetamine (2) 2
analgesics (2) 2
analgesics, opioid - chemistry (2) 2
anesthesiology (2) 2
anticonvulsants - administration & dosage (2) 2
anticonvulsants - adverse effects (2) 2
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Smoking, nicotine metabolism and cytochromes P450: Impact of genetic and regulatory variation
by Schoedel, Kerri Alexandra
2004, ISBN 0612944816
Variation in nicotine metabolism and cytochromes P450 (CYPs) may alter smoking risk and behaviour. Sources of regulatory variation in CYP2A (and CYP2B) and... 
Health Sciences, Toxicology | Health Sciences, Pharmacology
eBook
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Human abuse potential of brivaracetam in healthy recreational central nervous system depressant users
by Schoedel, Kerri A and Stockis, Armel and Sellers, Edward M
Epilepsy & Behavior, ISSN 1525-5050, 01/2018, Volume 78, pp. 194 - 201
Brivaracetam is a new antiepileptic drug indicated for adjunctive treatment of focal seizures in adults at a dose of 50–200 mg/day taken in two equal doses.... 
Antiepileptic drug | Alprazolam | Subjective measures | Brivaracetam | Abuse potential | Levetiracetam | SAFETY | PSYCHIATRY | CLINICAL NEUROLOGY | PARTIAL-ONSET SEIZURES | LIABILITY ASSESSMENT | CNS PHARMACODYNAMICS | PHARMACOKINETICS | DOUBLE-BLIND | BEHAVIORAL SCIENCES | PLACEBO-CONTROLLED TRIAL | ADJUNCTIVE BRIVARACETAM | ADVERSE EVENT PROFILE | Hypnotics and Sedatives - adverse effects | Central Nervous System Depressants - adverse effects | Humans | Middle Aged | Hypnotics and Sedatives - administration & dosage | Anticonvulsants - administration & dosage | Male | Anticonvulsants - pharmacology | Levetiracetam - adverse effects | Central Nervous System Depressants - pharmacology | Pyrrolidinones - administration & dosage | Young Adult | Anticonvulsants - adverse effects | Alprazolam - administration & dosage | Drug-Related Side Effects and Adverse Reactions | Pyrrolidinones - pharmacology | Adult | Female | Alprazolam - pharmacology | Pyrrolidinones - adverse effects | Double-Blind Method | Alprazolam - adverse effects | Levetiracetam - administration & dosage | Street Drugs - adverse effects | Cross-Over Studies | Euphoria | Adolescent | Central Nervous System Depressants - administration & dosage | Levetiracetam - pharmacology | Hypnotics and Sedatives - pharmacology | Drug abuse | Anticonvulsants | Seizures (Medicine) | Analysis | Central nervous system
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Randomized, Double-Blind, Placebo-A nd Active Comparator-Controlled Crossover Study Evaluating the Abuse Potential of the Antiepileptic Drug Lacosamide in Healthy Recreational Drug Users
by Schoedel, Kerri A and Andreas, Jens-Otto and Doty, Pamela and Eckhardt, Klaus and Sellers, Edward M
Journal of Clinical Psychopharmacology, ISSN 0271-0749, 12/2017, Volume 37, Issue 6, pp. 675 - 683
epilepsy | alprazolam | addiction | subjective effects | substance abuse
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Abuse liability assessment of eslicarbazepine acetate in healthy male and female recreational sedative users: A Phase I randomized controlled trial
by Levy-Cooperman, Naama and Schoedel, Kerri A and Chakraborty, Bijan and Blum, David and Cheng, Hailong
Epilepsy and Behavior, ISSN 1525-5050, 2016, Volume 61, pp. 63 - 71
Abstract Rationale Eslicarbazepine acetate (ESL) is a once-daily oral antiepileptic drug for the treatment of partial-onset seizures. Adverse events such as... 
Neurology | Human | Alprazolam | Clinical | Subjective measures | Abuse liability | Eslicarbazepine acetate | PLACEBO | MONOTHERAPY | EFFICACY | SAFETY | PSYCHIATRY | HUMANS | ADULTS | CLINICAL NEUROLOGY | PARTIAL-ONSET SEIZURES | DOUBLE-BLIND | BEHAVIORAL SCIENCES | MODULATION | Substance-Related Disorders - etiology | Dibenzazepines - administration & dosage | Recreation - psychology | Double-Blind Method | Hypnotics and Sedatives - adverse effects | Dibenzazepines - pharmacokinetics | Humans | Middle Aged | Hypnotics and Sedatives - administration & dosage | Alprazolam - adverse effects | Male | Dibenzazepines - adverse effects | Cross-Over Studies | Dose-Response Relationship, Drug | Young Adult | Dibenzazepines - pharmacology | Alprazolam - administration & dosage | Adolescent | Adult | Female | Hypnotics and Sedatives - pharmacology | Alprazolam - pharmacology | Women | Clinical trials | Liability (Law) | Health aspects | Analysis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Review of human abuse potential study methodology for abuse-deterrent formulations
by Schoedel, Kerri A and Setnik, Beatrice and Roland, Carl L and Pixton, G.C and Shram, M and Levy-Cooperman, Naama
Drug and Alcohol Dependence, ISSN 0376-8716, 2014, Volume 140, pp. e199 - e199
Psychiatry
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Reducing subject burden: Identifying critical measures in human abuse potential studies using factor analysis
by Levy-Cooperman, Naama and Mills, C and Shram, M.J and Schoedel, Kerri A
Drug and Alcohol Dependence, ISSN 0376-8716, 2013, Volume 140, pp. e121 - e121
Psychiatry
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Subjective and Physiological Effects of Oromucosal Sprays Containing Cannabinoids (Nabiximols): Potentials and Limitations for Psychosis Research
by A Schoedel, Kerri and Jane Harrison, Sarah
Current Pharmaceutical Design, ISSN 1381-6128, 11/2012, Volume 18, Issue 32, pp. 5008 - 5014
Cannabis use is associated with a spectrum of effects including euphoria, relaxation, anxiety, perceptual alterations, paranoia, and impairments in attention... 
Journal Article
Details down arrow
8. Full Text Randomized open-label drug-drug interaction trial of dextromethorphanquinidine and paroxetine in healthy volunteers
by Schoedel, Kerri A and Pope, Laura E and Sellers, Edward M
Clinical Drug Investigation, ISSN 1173-2563, 2012, Volume 32, Issue 3, pp. 157 - 169
emotional lability | paroxetine | quinidine | dextromethorphan
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Abuse deterrence testing: A dose ratio escalation study examining naloxone coadministered with intravenous hydromorphone in non-treatment-seeking, opioid-dependent drug users
by Levy-Cooperman, Naama and Schoedel, Kerri A and Reiz, Joseph L and Thompson, David and Chakaraborty, Bijan and Geoffroy, Pierre and Michalko, Kenneth J
Journal of Opioid Management, ISSN 1551-7489, 05/2016, Volume 12, Issue 3, pp. 165 - 180
To assess the reduction in intravenous (IV) abuse potential of hydromorphone from different dose ratio combinations with naloxone in opioid-dependent drug... 
Abuse-deterrent formulations | Abuse liability | Opioid-dependent | Opioid antagonist | Opioids | Hydromorphone - adverse effects | Injections, Intravenous | Double-Blind Method | Substance Withdrawal Syndrome - prevention & control | Humans | Hydromorphone - pharmacokinetics | Middle Aged | Male | Abuse-Deterrent Formulations | Cross-Over Studies | Dose-Response Relationship, Drug | Young Adult | Hydromorphone - administration & dosage | Naloxone - adverse effects | Adolescent | Adult | Female | Opioid-Related Disorders - prevention & control | Drug Therapy, Combination | Naloxone - administration & dosage | Naloxone - pharmacokinetics | Substance Withdrawal Syndrome - diagnosis
Journal Article
Details down arrow
10. Full Text CNS Drug Liabilities in Early Phase Clinical Trials
by Kerri Schoedel and Pierre Geoffroy
Applied Clinical Trials, ISSN 1064-8542, 05/2013, Volume 22, Issue 5, p. 24
In Phase I studies with healthy volunteers, the primary method used for evaluating the subjective effects of drugs is through the use of subjective... 
Studies | Professional liability | Clinical trials | Nervous system | Pharmaceutical industry
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text A Study of Potential Pharmacokinetic and Pharmacodynamic Interactions between Dextromethorphan/Quinidine and Memantine in Healthy Volunteers
by Pope, Laura E and Schoedel, Kerri A and Bartlett, Cynthia and Sellers, Edward M
Clinical Drug Investigation, ISSN 1173-2563, 08/2012, Volume 32, Issue 8, pp. e1 - e15
  Background and Objective: Dextromethorphan/quinidine (DMQ) is the first agent indicated for the treatment of pseudobulbar affect. Dextromethorphan, the... 
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text A study of potential pharmacokinetic and pharmacodynamic interactions between dextromethorphanquinidine and memantine in healthy volunteers
by Pope, Laura E and Schoedel, Kerri A and Bartlett, Cynthia and Sellers, Edward M
Clinical Drug Investigation, ISSN 1173-2563, 2012, Volume 32, Issue 8, pp. e1 - e15
pharmacokinetics | Dextromethorphan | drug interactions | quinidine | memantine
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text CNS drug liabilities in early phase clinical trials: only eight percent of CNS drugs will reach approval, in part because of the high adverse effects standards
by Schoedel, Kerri and Geoffroy, Pierre
Applied Clinical Trials, ISSN 1064-8542, 05/2013, Volume 22, Issue 5, p. 24
Physiological aspects | Research | Licensing, certification and accreditation | Central nervous system depressants | Analysis | Central nervous system
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Abuse potential assessment of cannabidiol (CBD) in recreational polydrug users: A randomized, double-blind, controlled trial
by Schoedel, Kerri A and Szeto, Isabella and Setnik, Beatrice and Sellers, Edward M and Levy-Cooperman, Naama and Mills, Catherine and Etges, Tilden and Sommerville, Kenneth
Epilepsy & Behavior, ISSN 1525-5050, 11/2018, Volume 88, pp. 162 - 171
Treatment with a highly purified oral solution of cannabidiol (CBD), derived from the plant L., demonstrated some evidence of central nervous system... 
Alprazolam | Cannabidiol | Abuse potential | Epilepsy | Dronabinol | DRAVET SYNDROME | LENNOX-GASTAUT SYNDROME | PSYCHIATRY | CLINICAL NEUROLOGY | MARIJUANA SMOKERS | LIABILITY ASSESSMENT | SEIZURES | PHARMACOLOGY | DELTA-TETRAHYDROCANNABINOL | BEHAVIORAL SCIENCES | ESLICARBAZEPINE ACETATE | DISCRIMINATIVE STIMULUS | ORAL CANNABIDIOL | Clinical trials | Analysis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Subjective and physiological effects of oromucosal sprays containing cannabinoids (nabiximols): potentials and limitations for psychosis research
by Schoedel, Kerri A and Harrison, Sarah Jane
Current pharmaceutical design, ISSN 1381-6128, 2012, Volume 18, Issue 32, pp. 5008 - 5014
Cannabis use is associated with a spectrum of effects including euphoria, relaxation, anxiety, perceptual alterations, paranoia, and impairments in attention... 
9-delta-tetrahydrocannabinol | psychosis model | SCHIZOPHRENIA | Cannabinoid | ORAL DELTA-TETRAHYDROCANNABINOL | THC | cannabidiol | MARIJUANA | prodromal syndrome | SATIVEX | DELTA-9-TETRAHYDROCANNABINOL | oromucosal | DOPAMINE | PHARMACOLOGY & PHARMACY | PEOPLE | WORKING-MEMORY | Drug Administration Routes | Cannabinoids - administration & dosage | Humans | Psychoses, Substance-Induced - etiology | Mouth Mucosa | Marijuana Abuse - complications | Cannabinoids - adverse effects
Journal Article
Details down arrow
16. Full Text Human abuse liability evaluation of CNS stimulant drugs
by Romach, Myroslava K and Schoedel, Kerri A and Sellers, Edward M
Neuropharmacology, ISSN 0028-3908, 12/2014, Volume 87, pp. 81 - 90
Psychoactive drugs that increase alertness, attention and concentration and energy, while also elevating mood, heart rate and blood pressure are referred to as... 
Clinical | Stimulant | Methodology | Human abuse potential | Subjective | ORAL METHYLPHENIDATE | RELEASE METHYLPHENIDATE | ADENOSINE A(2A) RECEPTOR | CENTER INVENTORY ARCI | RAPID DELIVERY | NEUROSCIENCES | CLINICAL-TRIALS | DOUBLE-BLIND | DOPAMINE | PHARMACOLOGY & PHARMACY | AMPHETAMINE | PARKINSONS-DISEASE | Drug Evaluation - methods | Self Administration | Substance-Related Disorders - prevention & control | Humans | Clinical Trials as Topic | Central Nervous System Stimulants - administration & dosage | Substance-Related Disorders - diagnosis | Drugs | Liability (Law) | Drug approval | Analysis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
17. Full Text Assessment of the Abuse Potential of Cebranopadol in Nondependent Recreational Opioid Users: A Phase 1 Randomized Controlled Study
by Göhler, Karin and Göhler, Karin and Sokolowska, Marta and Schoedel, Kerri A and Schoedel, Kerri A and Nemeth, Robert and Kleideiter, Elke and Kleideiter, Elke and Szeto, Isabella and Szeto, Isabella and Eerdekens, Marie-Henriette and Eerdekens, Marie-Henriette
Journal of clinical psychopharmacology, ISSN 0271-0749, 01/2019, Volume 39, Issue 1, pp. 46 - 56
Background: Cebranopadol is a nociceptin/ orphanin FQ peptide/ opioid receptor agonist with central antinociceptive activity. We hypothesize that this novel... 
NOP/opioid receptor agonist | hydromorphone | abuse potential | cebranopadol | MORPHINE | PSYCHIATRY | ACQUISITION | NOCICEPTIN/ORPHANIN FQ PEPTIDE | LIABILITY | NOP | DRUG-ABUSE | PAIN | FORMULATIONS | PHARMACOLOGY & PHARMACY | RECEPTOR AGONIST | RELEASE HYDROMORPHONE | Hydromorphone | Receptors | Research | Opioids | opioid receptor agonist | Original Contributions
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
18. Full Text Evaluation of the Relative Intranasal Abuse Potential of a Hydrocodone Extended-Release Tablet Formulated with Abuse-Deterrence Technology in Nondependent, Recreational Opioid Users
by Bond, Mary and Schoedel, Kerri A and Rabinovich-Guilatt, Laura and Gasior, Maciej and Tracewell, William and Malamut, Richard and Ma, Yuju and Webster, Lynn R
Pain Medicine, ISSN 1526-2375, 08/2018, Volume 19, Issue 8, pp. 1597 - 1612
Abstract Objective To assess the intranasal abuse potential of hydrocodone extended-release (ER) tablets developed with CIMA Abuse-Deterrence Technology... 
OXYCODONE | Hydrocodone | HEALTHY | Substance Abuse | TRENDS | Abuse Potential | Drug Liking | RATES | MEDICINE, GENERAL & INTERNAL | PHARMACOKINETICS | ANESTHESIOLOGY | Extended Release | Opioid Analgesics | Double-Blind Method | Tablets | Administration, Oral | Humans | Middle Aged | Male | Administration, Intranasal | Delayed-Action Preparations - administration & dosage | Cross-Over Studies | Young Adult | Hydrocodone - administration & dosage | Powders - pharmacokinetics | Analgesics, Opioid - administration & dosage | Analgesics, Opioid - pharmacokinetics | Delayed-Action Preparations - pharmacokinetics | Hydrocodone - pharmacokinetics | Opioid-Related Disorders | Adult | Female | Powders - administration & dosage | Drug abuse | Drug delivery systems | Statistical analysis | Narcotics | Opioids | Pain management | Clinical trials | Pharmacokinetics | Powder | OPIOIDS & SUBSTANCE USE DISORDERS SECTION
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
19. Full Text Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Crossover Study Evaluating the Abuse Potential of the Antiepileptic Drug Lacosamide in Healthy Recreational Drug Users
by Schoedel, KA and Andreas, JO and Doty, P and Eckhardt, K and Sellers, EM
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, ISSN 0271-0749, 12/2017, Volume 37, Issue 6, pp. 675 - 683
Purpose This phase 1, randomized, double-blind, placebo- and active comparator-controlled crossover study assessed the abuse potential of the antiepileptic... 
epilepsy | alprazolam | CONTROLLED-TRIAL | EFFICACY | SAFETY | PSYCHIATRY | addiction | ADULTS | LIABILITY | subjective effects | PARTIAL-ONSET SEIZURES | PREGABALIN ABUSE | TOLERABILITY | PHARMACOLOGY & PHARMACY | ADJUNCTIVE THERAPY | substance abuse | Double-Blind Method | Central Nervous System Depressants - adverse effects | Humans | Middle Aged | Alprazolam - adverse effects | Acetamides - pharmacology | Anticonvulsants - administration & dosage | Male | Anticonvulsants - pharmacology | Central Nervous System Depressants - pharmacology | Cross-Over Studies | Young Adult | Anticonvulsants - adverse effects | Alprazolam - administration & dosage | Drug-Related Side Effects and Adverse Reactions | Central Nervous System Depressants - administration & dosage | Acetamides - adverse effects | Adult | Female | Substance-Related Disorders | Alprazolam - pharmacology | Acetamides - administration & dosage | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
20. Full Text Assessment of Pharmacokinetic and Pharmacodynamic Interactions between Albumin-Fused Mutated Butyrylcholinesterase and Intravenously Administered Cocaine in Recreational Cocaine Users
by Shram, Megan J and Cohen-Barak, Orit and Chakraborty, Bijan and Bassan, Merav and Schoedel, Kerri A and Hallak, Hussein and Eyal, Eli and Weiss, Sivan and Gilgun, Yossi and Sellers, Edward M and Faulknor, Janice and Spiegelstein, Ofer
Journal of Clinical Psychopharmacology, ISSN 0271-0749, 08/2015, Volume 35, Issue 4, pp. 396 - 405
Introduction Cocaine dependence presents a major public health issue, and to date, no pharmacotherapies are approved for its treatment. TV-1380 is a novel... 
Benzoylecgonine | ecgonine methyl ester | pharmacokinetic | albumin-fused butyrylcholinesterase | cocaine | DRUG | SUBSTANCE-ABUSE | ABUSE LIABILITY ASSESSMENT | PSYCHIATRY | DORSAL STRIATUM | DOPAMINE | RATS | HUMANS | SEEKING | PHARMACOLOGY & PHARMACY | ADDICTION | HYDROLASE | Butyrylcholinesterase - blood | Cocaine - blood | Injections, Intravenous | Double-Blind Method | Albumins - metabolism | Humans | Middle Aged | Albumins - administration & dosage | Male | Butyrylcholinesterase - administration & dosage | Dose-Response Relationship, Drug | Young Adult | Cocaine - administration & dosage | Adolescent | Drug Interactions - physiology | Adult | Female | Street Drugs - blood | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.